Open AccessA case of hypereosinophilia with digital ischaemia successfully treated with intravenous prostaglandin E 1
Author(s) -
Kaga M.,
Takeuchi H.,
Iwahara K.,
Ihara H.
Publication year - 2021
Publication title -
skin health and disease
Language(s) - English
Resource type - Journals
ISSN - 2690-442X
DOI - 10.1002/ski2.32
Subject(s) - hypereosinophilia , medicine , ischemia , benralizumab , eosinophilic , eosinophilia , anesthesia , eosinophil , pathology , mepolizumab , asthma
In the therapeutic management of eosinophilic disorder, it is important to prevent hypereosinophilia (HE)‐related organ damage even in the process of diagnosis. We describe here a unique clinical and histopathological findings of the patient with HE accompanied with digital ischaemia. Treatment with intravenous prostaglandin E 1 was essential for digital ischaemia in our case while benralizumab, humanized monoclonal antibody against interleukin‐5 receptorα, did not affect. Our case suggests an earlier intervention for digital ischaemia in the therapeutic management of eosiniphilic disorder.